Home/Filings/4/0001209191-16-110833
4//SEC Filing

Eiger BioPharmaceuticals, Inc. 4

Accession 0001209191-16-110833

CIK 0001305253operating

Filed

Mar 27, 8:00 PM ET

Accepted

Mar 28, 9:13 PM ET

Size

5.8 KB

Accession

0001209191-16-110833

Insider Transaction Report

Form 4
Period: 2016-03-23
WELCH JAMES H
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2016-03-23+57,57157,571 total
    Exercise: $15.89Exp: 2026-03-23Common Stock (57,571 underlying)
Footnotes (2)
  • [F1]The option will vest as to 25% of the option shares on March 23, 2017 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.
  • [F2]The option is subject to shareholder approval of an amendment to the Celladon Corporation 2013 Equity Incentive Plan. This is a voluntary early filing.

Issuer

Eiger BioPharmaceuticals, Inc.

CIK 0001305253

Entity typeoperating

Related Parties

1
  • filerCIK 0001305253

Filing Metadata

Form type
4
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 9:13 PM ET
Size
5.8 KB